CELU
CELU
NASDAQ · Biotechnology

Celularity Inc-A

$0.68
-0.07 (-8.81%)
As of Nov 12, 10:16 PM ET ·
Financial Highlights (FY 2026)
Revenue
33.65M
Net Income
-116,252,241
Gross Margin
24.4%
Profit Margin
-345.5%
Rev Growth
+13.9%
D/E Ratio
4.75
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 24.4% 24.4% 53.6% 53.6%
Operating Margin -274.5% -247.1% 20.6% 21.3%
Profit Margin -345.5% -328.2% 22.1% 19.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 33.65M 29.55M 10.25M 10.35M
Gross Profit 8.21M 7.21M 5.50M 5.55M
Operating Income -92,388,722 -73,015,322 2.11M 2.20M
Net Income -116,252,241 -91,874,795 2.27M 1.98M
Gross Margin 24.4% 24.4% 53.6% 53.6%
Operating Margin -274.5% -247.1% 20.6% 21.3%
Profit Margin -345.5% -328.2% 22.1% 19.1%
Rev Growth +13.9% +13.9% +24.9% +1.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 10.19M 10.19M 12.27M 11.63M
Total Equity 2.14M 2.14M 14.31M 15.01M
D/E Ratio 4.75 4.75 0.86 0.77
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -90,496,281 -75,493,033 3.06M 3.48M
Free Cash Flow — — 1.07M 1.08M